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AbstrAct
We investigated whether impaired regulation of bone morphogenetic protein-2 
(BMP-2) via epigenetic pathways is associated with renal cell carcinoma (RCC) 
pathogenesis. Expression and CpG methylation of the BMP-2 gene were analyzed 
using RCC cell lines, and 96 matched RCC and normal renal tissues. We also performed 
functional analysis using BMP-2 restored RCC cells. A significant association of BMP-
2 mRNA expression was also found with advanced tumor stage and lymph node 
involvement, while lower BMP-2 mRNA expression was significantly associated with 
poor overall survival after radical nephrectomy. In RCC cells, BMP-2 restoration 
significantly inhibited cell proliferation, migration, invasion, and colony formation. 
In addition, BMP-2 overexpression induced p21WAF1/CIP1 and p27KIP1 expression, and 
cellular apoptosis in RCC cells. BMP-2 mRNA expression was significantly enhanced 
in RCC cells by 5-aza-2’-deoxycitidine treatment. The prevalence of BMP-2 promoter 
methylation was significantly greater and BMP-2 mRNA expression was significantly 
lower in RCC samples as compared to normal kidney samples. Furthermore, a 
significant correlation was found between BMP-2 promoter methylation and mRNA 
transcription in tumors. Aberrant BMP-2 methylation and the resultant loss of BMP-2 
expression may be a useful molecular marker for designing improved diagnostic and 
therapeutic strategies for RCC.
IntroductIon
Renal cell carcinoma (RCC) is one of the most 
commonly encountered urological cancers, accounting 
for 2-3% of all tumor malignancies in adults [1]. The 
major cause of death from RCC is metastasis and the 
5-year survival rate for affected patients with metastasis 
is less than 10% [2]. Indeed, 25% of RCC patients show 
metastasis at the time of diagnosis [3]. In addition, 
up to one third of localized RCC patients experience 
recurrence and/or metastasis after curative radical surgery 
[4]. Although several prognostic models of RCC based 
on clinical parameters have been developed [5, 6], 
they all lack accuracy, probably due to the biologically 
heterogeneous nature of the disease. Therefore, efficient 
and reliable molecular biomarkers to predict cancer 
progression are urgently needed to develop better 
therapeutic and diagnostic strategies.
Bone morphogenetic protein 2 (BMP-2), a member 
of the transforming growth factor (TGF)-β superfamily, 
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has potent activities to induce the entire cascade of 
cartilage and ectopic osteogenesis [7]. In addition to 
bone formation, BMP-2 plays important roles in cell 
differentiation, proliferation, morphogenesis, and 
apoptosis [8-11]. Similar to TGF-β, BMP-2 exerts its effect 
via 2 types of transmembrane serine/threonine kinase 
receptors; BMP receptor type I (BMPRI) and II (BMPRII). 
BMP-2 binding to BMPRII triggers phosphorylation of 
BMPRI, and activation of downstream signaling via Sma- 
and Mad-related (Smad) proteins; e.g., Smad1, Smad5, 
and Smad8. Phosphorylated Smad1/5/8 subsequently 
form complexes with Smad4 and then translocates to 
the nucleus to regulate a variety of genes that arrest cell 
growth and induce apoptosis [12, 13].
BMP-2 is thought to be a putative tumor-suppressor 
gene in several types of cancer (i.e., gastric, colon, 
prostate, adrenal) [10, 11, 14-17]. Recently, Wang et al. 
[18] demonstrated that BMP-2 inhibits RCC growth by 
causing cell cycle arrest in the G1 phase. On the other 
hand, Markić et al. [19] showed that expression levels of 
BMP-2 were strongly elevated with increased TNM stage 
in clinical RCC. However, the biological effects of BMP-2 
on RCC development and progression remain to be fully 
elucidated, because only limited information is available 
for BMP-2 in human RCC. 
DNA methylation of CpG islands involving the 
promoter of tumor suppressor genes is a well-known 
mechanism underlying gene silencing, which leads to 
functional loss as a tumor suppressor [20, 21]. Previous 
studies have shown that the expression level of BMP-2 
is frequently down-regulated because of promoter CpG 
hypermethylation [14, 15]. Therefore, we hypothesized 
that impaired regulation of BMP-2 via an epigenetic 
pathway may be associated with RCC pathogenesis. 
In the present study, we assessed the correlation 
between expression of the BMP-2 gene and epigenetic 
mechanisms using 2 RCC cells lines, as well as 96 
matched RCC and normal renal tissues. We also evaluated 
the association of BMP-2 expression and BMP-2 CpG 
methylation status with clinical parameters and prognosis 
in cases of RCC following radical nephrectomy. Finally, 
we over-expressed BMP-2 in kidney cancer cells and 
performed functional analyses.
results
bMP-2 is down-regulated in rcc cell lines and 
rcc tissues
To determine BMP-2 mRNA and protein expression, 
RT-PCR and Western blotting analyses were performed 
using HK-2, Caki-1, and Caki-2 cells. Both BMP-2 
mRNA (Fig. 1A) and protein expression (Fig. 1B) were 
significantly down-regulated in the RCC cell lines as 
compared with the nonmalignant HK-2 cells. Next, 
BMP-2 expression was evaluated in 96 RCC samples and 
matched normal renal tissues. As shown in Figure 1C, 
RCC showed a lower level of BMP-2 mRNA expression 
in comparison with that of the corresponding normal renal 
tissues (P=0.0144). We also investigated the expression of 
BMP-2 using immunohistochemical staining. BMP-2 was 
significantly higher in the tubular cytoplasm of normal 
renal cells as compared to that of the RCC (P<0.0001; 
Fig. 1D, E). Furthermore, there was a positive correlation 
between BMP-2 mRNA transcription and protein level 
(data not shown). 
bMP-2 is regulated by promoter cpG methylation 
in rcc
We used 5-aza-dC to screen for the epigenetic status 
of BMP-2 in RCC cell lines. In Caki-1 and Caki-2 cells, 
the expression level of the BMP-2 mRNA transcript was 
significantly increased after 5-aza-dC treatment (Fig. 
2C), suggesting that promoter CpG methylation may 
be associated with BMP-2 expression in these cells. To 
confirm the relationship between CpG methylation and 
expression of the BMP-2 mRNA transcript, we performed 
MSP analysis. As shown in Figure 2A and B, MSP and 
USP primers were designed based on a previous report 
[14]. Caki-1 and Caki-2 cells, which slightly express the 
BMP-2 gene, were partially methylated (Fig. 2D).
We further performed MSP analysis of the 96 RCC 
tissue samples. Representative MSP and USP bands of 
8 matched RCC and normal renal tissues are shown in 
Figure 2E. Most RCC tissues showed both MSP and USP 
bands, whereas most normal renal tissues showed only 
a USP band. Forty-six of the 96 RCC tissues (47.9%) 
were found to be positive for BMP-2 methylation, while 
16 of 96 normal kidney tissues (17.7%) were positive 
(P<0.0001; Fig. 2F). Bisulfite DNA sequencing was also 
performed to confirm whether the MSP bands reflected the 
true methylation status of the CpG sites. Representative 
bisulfite DNA sequencing findings for RCC and normal 
renal tissues are shown in Figure 2G. In a normal kidney 
sample (No. 2 Normal), the majority of cytosines within 
CpG sites were completely converted to thymines (un-
methylated) after bisulfite modification. On the other hand, 
the majority of cytosines remained virtually unchanged 
after bisulfite modification in an RCC sample (No. 8 
Tumor). These results indicated that methylation analysis 
using a combination of MSP and USP was consistent with 
the results from bisulfite DNA sequencing.
Next, we evaluated the correlation between 
methylation status and BMP-2 expression in RCC 
samples. A significant inverse correlation was found 
between BMP-2 mRNA transcripts and methylation of 
the BMP-2 promoter in the RCC samples (P=0.0079; Fig. 
3A). In addition, RCC samples with an un-methylated alle 
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Figure 1: bMP-2 expression in rcc cell lines and tissues. (A) Relative BMP-2 mRNA expression levels in RCC cell lines 
(Caki-1 and Caki-2) and normal kidney cells (HK-2). The expression level of BMP-2 mRNA was significantly down-regulated in Caki-2 
and Caki-2 cells. *P<0.0001. (B) Representative immunoblotting image displaying BMP-2 expression in HK-2, Caki-1, and Caki-2 cells. 
BMP-2 protein was down-regulated in RCC as compared to HK-2 cells. (C) Expression of BMP-2 mRNA in clinical samples. RCC samples 
showed a lower level of BMP-2 mRNA expression in comparison with normal renal tissues (p=0.0144). (D) BMP-2 staining scores of 
clinical samples. BMP-2 protein expression in RCC samples was significantly lower as compared to normal kidney tissues (P<0.0001). (E) 
Representative immunostaining of BMP-2 in a clinical sample. (a) Strong BMP-2 staining was more common in the adjacent normal cells 
than in the cancer cells (×100). (b) Strong cytoplasmic and/or nuclear staining of BMP-2 was observed in normal renal tubules (×200). (c) 
Weak cytoplasmic staining of BMP-2 was observed in RCC tumors (×200). 
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Figure 2: Analysis of BMP-2 methylation in rcc cell lines and clinical samples. (A) Schema of BMP-2 promoter and 
locations of the primers. The universal primers (F, forward; R, reverse) used did not contain any CpG sites within the primer sequence. 
The F and R methylation-specific PCR (MSP) primers contained 3 and 4 CpG sites, respectively, with un-methylation-specific PCR (USP) 
primers designed in the same manner. (B) Primer sequences. Boldface indicates difference with modified sequence, and underline indicates 
changes between methylated and un-methylated sequences after bisulfite modification. (C) Alteration of BMP-2 expression before and after 
de-methylation. In both Caki-1 and Caki-2 cell lines, the expression level of the mRNA transcript of BMP-2 was significantly increased 
after 5-aza-dC treatment as compared with that before de-methylation. *P<0.0001. (D) MSP and USP bands in Caki-1 and Caki-2 cells, 
which were partially methylated. (E) Representative results of MSP and USP of the BMP-2 promoter in clinical samples. Top and bottom 
show MSP and USP bands, respectively, from the same samples. (F) BMP-2 methylation status in clinical samples. The prevalence of BMP-
2 methylation was significantly higher in RCC samples than normal renal tissues (P<0.0001). (G) Typical bisulfite DNA sequencing in 
normal kidney and RCC samples. In the normal kidney samples, the majority of cytosines within the CpG sites were completely converted 
to thymines after bisulfite modification, whereas in the RCC samples, the majority of cytosines remained virtually unchanged after bisulfite 
modification. Horizontal bar, CpG sites; UM, un-methylation; M, methylation.
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of BMP-2 exhibited positive staining, while methylated 
RCC samples exhibited negative staining (Fig. 3B). Thus, 
expression of BMP-2 may be silenced via promoter CpG 
methylation in RCC.
BMP-2 methylation and resultant loss of bMP-2 
correlated with poor prognosis in rcc 
Clinicopathological findings of the 96 RCC patients 
with BMP-2 methylation status are shown in Table 1. 
BMP-2 methylation was found to have a significant 
association with infiltrative growth pattern and systematic 
Figure 3: effects of bMP-2 methylation status on the expression level of bMP-2 mrnA and association with 
clinicopathological findings. (A) Relationship between BMP-2 methylation status and BMP-2 mRNA expression. In RCC samples, 
BMP-2 methylation (+) resulted in a significantly lower level of expression of the BMP-2 mRNA transcript as compared to BMP-2 un-
methylation (-) (p=0.0079). (B) Representative immunostaining of BMP-2 in RCC samples. Un-methylated RCC cells exhibited positive 
staining (×200). Methylated RCC cells exhibited negative staining (×200). (C, D) Relationships of BMP-2 expression with clinicopathological 
findings. A lower level of expression of the BMP-2 mRNA transcript was significantly associated with a higher prevalence of cases with 
advanced disease (greater than III) (p=0.0065) and lymph node involvement (p=0.0224). (E, F) Kaplan-Meier curves for overall survival 
after radical nephrectomy. Both methylation (+) and lower BMP-2 expression were significantly associated with poor prognosis (P=0.0224, 
P=0.0039, respectively).
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metastasis (P=0.038, P=0.0024, respectively). Also, the 
RCC patients with positive methylation had a higher 
stage as compared to those with negative methylation, 
though the difference did not reach statistical significance 
(P=0.0701). However, there was no significant association 
of BMP-2 methylation with tumor grade found. 
Correlations of clinicopathological findings with BMP-2 
mRNA expression are shown in Figure 3C and D. A lower 
expression level of the BMP-2 mRNA transcript was also 
significantly correlated with high-stage disease and lymph 
node involvement (P=0.0065, P=0.024, respectively).
Kaplan-Meier curves for overall survival (OS) after 
radical nephrectomy are shown in Figure 3E and F. OS 
in the BMP-2 methylated group was significantly worse 
in comparison with that in the BMP-2 un-methylated 
group (P=0.025; Fig. 3E). Likewise, when the expression 
level of the BMP-2 mRNA transcript was divided into 
2 groups based on mean values, lower expression was 
significantly associated with poor prognosis (P=0.039; 
Fig. 3F). As shown in Table 2, BMP-2 methylation 
status, BMP-2 mRNA expression, tumor stage, and tumor 
grade were identified as significant factors contributing 
to OS in univariate analysis. When these variables were 
subjected to a multivariate model, BMP-2 expression and 
tumor stage were shown to be significantly independent 
predictors for OS after a radical nephrectomy.
bMP-2 inhibits renal cancer cell viability, 
migration, invasion, and colony-formation
To determine the functional significance of BMP-2 
in RCC, we examined whether over-expression of BMP-
2 has effects on cell viability, migration and invasion 
properties, and colony-formation ability of RCC cell 
lines. Initially, mRNA expression of the BMP-2 receptors 
BMPRIa, BMPRIb, and BMPRII was evaluated, because 
BMP-2 induces a physiological response via their 
activation [12, 13]. As shown in Supplementary Figure S1, 
all of the BMP receptors were found to be expressed in 
Caki-1 and Caki-2 cells, consistent with previous findings 
[18]. Our result indicates that RCC cells have a potential 
capability of being activated by BMP-2, though they have 
lower levels of BMPRII as compared to HK-2 cells.
After transient transfection of a plasmid containing 
human BMP-2 into Caki-1 and Caki-2 cells, significant 
amounts of BMP-2 protein were detected by Western 
blotting (Fig. 4A). Cell proliferation (Fig. 4B) and 
wound healing (Fig. 4C) results demonstrated significant 
inhibition with BMP-2 transfectants for both Caki-
1 and Caki-2 cells as compared to the control vector 
transfectants. Matrigel invasion assay also showed that 
the number of invaded cells was significantly decreased 
in the BMP-2 transfectants as compared with their control 
counterparts (Fig. 4D). In addition, overexpression of 
BMP-2 inhibited colony-formation in both Caki-1 and 
Caki-2 cells (Fig. 4E). Thus, these results suggest that 
BMP-2 plays an important role in RCC progression.
bMP-2 induces p21WAF1/cIP1 and p27KIP1 expression 
in rcc via the smad pathway
A previous study indicated that the anti-proliferative 
effect of BMP-2 in RCC cell lines may be due to cell cycle 
arrest in the G1 phase [18]. In addition, accumulation of 
p21WAF1/CIP1 and/or p27KIP1 in response to activation of 
the BMP-Smad pathway contributes to growth arrest in 
several types of cancer [22-25]. Therefore we examined 
the expression of Smad1/5/8, phospho-Smad1/5/8, 
and several cell cycle regulatory genes using Western 
analysis. As shown in Figure 5A, expression of phospho-
Smad1/5/8, p21WAF1/CIP1, and p27KIP1 proteins were 
significantly increased after transfection with BMP-2 in 
Caki-1 and Caki-2 cells. Conversely, expression of Cdk2 
protein in BMP-2 transfectants in both RCC cell lines was 
significantly decreased in comparison with the control. 
Next, we examined the mRNA expression of 
p21WAF1/CIP1 and p27KIP1 in clinical samples. That of p27KIP1 
was significantly higher in the RCC samples than in the 
normal renal tissues (P<0.0001; Fig. 5B). Interestingly, 
there was a significant inverse correlation between BMP-
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2 mRNA and p27KIP1 mRNA expression (P<0.0001; Fig. 
5C). As for p21WAF1/CIP1, there was no significant difference 
in mRNA levels between the RCC samples and normal 
renal tissues (data not shown). 
bMP-2 effectively induces cellular apoptosis in 
rcc cells
Since BMP-2 restoration significantly inhibited 
proliferation, migration, invasion, and colony formation 
in RCC cell lines, we hypothesized that its expression 
Figure 4: effects of bMP-2 overexpression on cell proliferation, migration, invasion, and colony-formation. (A) BMP-2 
expression level in RCC cell lines (Caki-1, Caki-2) were determined by immunoblotting analysis at 48 hours after transfection of a plasmid 
containing human BMP-2. (B) Cell viability was analyzed using an MTS cell proliferation assay at 24, 48, 72, and 96 hours after transient 
transfection. Overexpression of BMP-2 significantly inhibited cell viability. *P<0.05, **P<0.01. (C) Representative images from wound 
healing assay. After transfection (48 hours), a wound was formed by scraping, then measured 24 hours later. Over-expression of BMP-2 
significantly inhibited cell migration. *P<0.0001. (D) Representative images from invasion assay. Overexpression of BMP-2 resulted in 
significantly decreased cell invasion. *P<0.0001. (E) Overexpression of BMP-2 significantly inhibited colony formation ability. *P<0.01.
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may induce apoptosis. The results of apoptosis assays 
of Caki-1 and Caki-2 cells performed 24 hours post-
transfection are shown in Figure 6A and B. Apoptotic 
and early apoptotic fractions (upper right and lower 
right, respectively, in quadrant images) were significantly 
greater in BMP-2 transfectants as compared to the vector 
control. These differences were also seen in both Caki-1 
and Caki-2 cells at 48 hours after transfection (data not 
shown). These findings indicate a pro-apoptotic role for 
BMP-2, as well as its effects on the apoptotic pathway 
and regulation of tumorigenicity. In our recent study, we 
found that growth arrest and DNA damage inducible gene 
45α (GADD45α) may play important roles in human RCC 
apoptosis [26]. Therefore, we examined the expression of 
several apoptotic proteins and GADD45α protein using 
Western blot analysis. As shown in Figure 6C, BMP-2 
over-expression caused an increase in cleaved caspase-3 
in both Caki-1 and Caki-2 cells, further supporting the 
pro-apoptotic role of BMP-2. Furthermore, GADD45α 
was up-regulated, indicating that overexpression of BMP-
2 induced GADD45α and apoptotic effects. Figure 7 
indicates the putative BMP-2 pathway in RCC on the basis 
of our results and previous studies [12, 13, 25, 27].
dIscussIon
 The incidence of RCC has been steadily increasing 
over recent decades in North America as well as Japan 
[28, 29]. Although currently employed molecular targeted 
drugs may be promising as treatment to prevent tumor 
progression [30, 31], they have not shown robust anti-
tumor effects. Therefore, increased understanding of the 
process of tumor progression may contribute to better 
treatment options for RCC patients. To date, several 
studies have shown that BMP-2 inhibits the growth of 
tumor cells in various types of cancer including RCC [10, 
11, 14-18]. With this background in mind, we focused 
on the role of BMP-2 in RCC tumorigenesis. Our results 
demonstrated a potential prognostic role for BMP-2 in 
RCC based on its significantly lower expression in patients 
with advanced stage and lymph node involvement. We 
also found that lower OS probability was significantly 
associated with lower BMP-2 expression. Furthermore, 
multivariate analysis clearly demonstrated the prognostic 
relevance of BMP-2 expression to predict OS after 
surgery. Thus, BMP-2 has a strong tumor suppressive 
potential in human RCC and may be useful for predicting 
Figure 5: effect of bMP-2 overexpression on cell cycle regulatory genes. (A) Immunoblotting analysis of Smad1/5/8, phospho-
Smad1/5/8, p21WAF1/CIP1, p27KIP1, and Cdk2 in control and BMP-2 transfected Caki-1 and Caki-2 cells. GAPDH was used as a loading 
control. (B) p27KIP1 mRNA expression in RCC samples and corresponding normal renal tissues. The p27KIP1 mRNA transcription was 
significantly lower in RCC samples than in normal renal tissues (P<0.0001). (C) Relationship of BMP-2 with p27KIP1 in RCC samples. A 
significant inverse correlation was found between BMP-2 mRNA expression and p27KIP1 mRNA expression in RCC samples (P<0.0001).
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OS following radical nephrectomy.
DNA methylation is one of the most common 
epigenetic changes that occurs in human cancers 
and many tumor-related genes are silenced by DNA 
hypermethylation in RCC [32, 33].It has been reported 
that BMP-2 expression is frequently regulated by DNA 
hypermethylation in colorectal and gastric cancers [14, 
15]. Therefore, we evaluated whether BMP-2 expression 
is regulated by alteration of CpG methylation in RCC. 
Both Caki-1 and Caki-2 cells showed a significant increase 
in BMP-2 mRNA expression following 5 aza-dC treatment 
compared to non-treated cells and MSP analysis suggested 
that CpG hypermethylation regulates BMP-2 gene 
expression in human RCC cells. We also found that the 
prevalence of BMP-2 CpG methylation was significantly 
higher in RCC samples than normal renal tissues by MSP 
analysis and bisulfite DNA sequencings. In addition, 
both BMP-2 mRNA and protein expression levels were 
significantly lower in methylated than none-methylated 
RCC samples, indicating epigenetic regulation of BMP-
2 in the clinical samples as well. Interestingly, BMP-2 
methylation status was correlated with poor prognostic 
factors (i.e., infiltrative growth pattern and systematic 
metastasis) and shorter OS as well as BMP-2 expression. 
Figure 6: effects of bMP-2 overexpression on apoptosis. (A) Apoptosis assays with Caki-1 and Caki-2 cells were performed at 24 
hours after transfection. Representative quadrant figures of control vector BMP-2 transfectants in Caki-1 (upper) and Caki-2 (lower) cells. 
(B) Bar chart indicates the ratio of apoptotic cell fractions (early plus apoptotic cells) in BMP-2 transfectants as compared with the control. 
Data for apoptotic cell fractions are expressed as the relative value for the average expression of the control vector transfectant. *P<0.01, 
**P<0.001. (C) Immunoblotting analysis of apoptotic markers and GADD45β in control and BMP-2 transfected Caki-1 and Caki-2 cells. 
GAPDH was used as a loading control.
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This is the first study to report that the expression of BMP-
2 is regulated by promoter CpG methylation in RCC.
Overexpression of BMP-2 has been found to 
decrease cell proliferation, migration, and invasiveness 
of human colon cancer cell lines [10].We also noted that 
BMP-2 re-expression strongly inhibited these activities 
in RCC cell lines. Previous results indicate that BMP-2 
blocs transition of the cell cycle from the G1 to S phase, 
which then inhibits proliferation of several types of 
cancer [11, 14, 18]. These anti-proliferative effects seem 
to be responsible for the increased phosphorylation of 
Smad1/5/8, and subsequent induction of cyclin-dependent 
kinase inhibitors such as p21WAF1/CIP1 and p27KIP1 [22-25]. 
These two proteins inhibit the activity of the cyclin E/
Cdk2 binary complex, which is required for G1/transition 
[34-36]. Clinically, accumulation of altered cell cycle 
regulators serves as an independent prognostic factor in 
RCC [37, 38]. In this study, we demonstrated that the 
expression of phospo-Smad1/5/8, p21WAF1/CIP1, and p27KIP1 
were up-regulated, while that of Cdk2 was down-regulated 
after BMP-2 restoration in RCC cell lines. Also, a positive 
correlation between BMP-2 and p27KIP1 mRNA levels 
was found in the RCC samples. These results suggest 
that BMP-2-induced growth suppression may be partly 
mediated by induction of p21WAF1/CIP1 and/or p27KIP1 via 
activation of a SMAD-dependent signaling pathway in 
RCC (Figure 7).
The present study is the first to clearly demonstrate 
that over expression of BMP-2 induces a significantly 
increased level of apoptosis in RCC cell lines. Other 
studies have reported that the anti-proliferative effect of 
BMP-2 in different tumor cell lines, including gastric, 
colon, and leukemia, may involve induction of apoptosis 
[8-10]. However, the precise mechanism of BMP-
2-induced apoptosis in cancer cells remains unclear. 
GADD45 proteins have been implicated in stress response, 
cell cycle arrest, apoptosis [39, 40], and have also been 
linked to c-Jun NH (2)-terminal kinase-mediated and 
mitochondria-mediated cell death [27]. Interestingly 
GADD45β, a member of the GADD45 family, has been 
proposed to be a major BMP-2 responsive gene induced 
in chondrocytes [41]. In addition, Tront et al. [42] found 
that GADD45α may have a tumor suppressive function 
in breast cancer. We also recently reported that down-
regulation of GADD45α inhibits cell death in RCC cell 
lines [26]. In light of these observations, we sought to 
determine whether GADD45α is associated with BMP-2-
mediated apoptosis and found GADD45α overexpression 
following BMP-2 restoration in RCC cell lines. Thus, 
GADD45α may play an essential role in BMP-2-mediated 
apoptosis in RCC cells (Figure 7), though further research 
is required to verify our findings.
In summary, our findings show that BMP-2 is an 
important tumor suppressor that is down-regulated by 
Figure 7: schema of bMP-2/smad signaling pathway in rcc. BMP-2 expression is regulated by DNA promoter methylation. 
BMP-2 may cause the induction of GADD45a, p21 and p27 expression through the activation of Smad pathway. GADD45a will induce 
apoptosis via caspase cascade. In addition, p21 and p27 will induce cell cycle arrest by inhibiting CDK2. These cell cycle arrest and 
apoptotic effect may play an important role in the inhibition of tumor proliferation in RCC.
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promoter CpG hypermethylation in RCC. BMP-2 up-
regulates p21WAF1/CIP1 and p27KIP1 expression and mediates 
apoptosis causing inhibition of RCC proliferation. Our 
results strongly suggest that aberrant BMP-2 methylation 
and the resultant loss of BMP-2 expression may be useful 
as a biomarker for designing improved diagnostic and 
therapeutic strategies for advanced RCC.
MAterIAls And Methods
rcc tissue samples
Ninety-six matched renal cell carcinoma (90 clear 
cell carcinomas, 6 papillary carcinomas) and normal 
renal tissues were obtained from the stocks of Shimane 
University Hospital (Izumo, Japan). Median patient age at 
surgery was 63 years old (range 16-87 years). Of the 96 
patients, 63 were males and 41 of the lesions were located 
on the right side. Fifty patients had a stage (Robson’s 
classification) I, 15 patients a stage II, 20 a stage III, and 
10 a stage IV. Thirty-three (34.4%) patients had tumor 
grade 1, 53 (55.6%) were tumor grade 2, and the remaining 
10 (10.4%) were tumor grade 3. Of the 96patients, 11 
(11.5%) had metastatic disease at the initial diagnosis. 
Each normal renal and RCC tissue specimen was halved, 
then one half was fixed in 10% buffered formalin (pH 7.0) 
and embedded in paraffin wax, with 5-mm-thick sections 
subjected to H&E staining for histologic evaluation. The 
remaining half of each sample was immediately frozen 
and stored at -80°C for DNA and RNA extraction. Written 
informed consent was obtained from each patient for 
molecular analysis of the resected specimens and the study 
protocol was approved by the local ethnical committee of 
Shimane University Faculty of Medicine.
cell lines and reagents
A human renal proximal tubule epithelial cell 
line, HK-2, and renal cancer cell lines Caki-1 and 
Caki-2 were obtained from the American Type Culture 
Collection (Manassas, VA). Keratinocyte serum-free 
medium (K-SFM), bovine pituitary extract (BPE), and 
recombinant epidermal growth factor (rEGF) were 
purchased from Invitrogen (Carlsbad, CA). McCoy’s 5A 
and Opti-minimum essential medium were obtained from 
the UCSG Cell Culture Facility (San Francisco, CA). 
Fetal bovine serum (FBS) came from Atlanta Biologicals 
(Lawrenceville, GA).
cell culture
Caki-1 and Caki-2 cells were cultured in McCoy’s 
5A medium supplemented with 10% FBS. HK-2 cells 
were maintained in K-SFM supplemented with 0.05 mg/
ml BPE and 5 ng/ml rEGF. All cell lines were maintained 
at 37°C in a humidified atmosphere composed of 5% CO2 
and 95% air.
nucleic acid extraction
Genomic DNA from kidney samples was extracted 
using a QIAamp Tissue kit (Qiagen, Valencia, CA) and 
precipitated with ethanol. Genomic DNA from cell 
lines was extracted using DNAzol reagent (Invitrogen 
Life Technologies, San Diego, CA) and total RNA was 
extracted with TRI reagent (Molecular Research Center, 
Cincinnati, OH), according to the manufacturer’s 
instructions. RNA pellets obtained after isopropanol 
and ethanol precipitation were dried, resuspended in 25 
μL of RNase-free water, and stored in aliquots at -80°C 
until reverse transcribed. The concentrations of DNA and 
RNA were determined with a spectrophotometer, and their 
integrity was checked by gel electrophoresis. 
cDNA preparation and gene quantification
Using 1 μg of RNA, 0.5 μg of oligo-dT primer, and 
0.5 units of RNase inhibitor, cDNA was constructed using 
reverse transcriptase (Promega). The mRNA transcript 
levels of BMP-2, BMPR1a, BMPR1b, BMPR2, p21WAF1/CIP1, 
and p27KIP1 were measured with a 7500 Fast Real-Time 
PCR System (Applied BioSystem), with glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) as the reference 
gene. For clinical samples, a standard curve was generated 
using a serial dilution of the external standard. The level 
of expression was calculated as the ratio of the target gene 
to that of the reference GAPDH. For cell line samples, 
the data was analyzed using the delta-delta Ct method to 
calculate the fold-change.
Treatment with 5-aza-2′-deoxycytidine
To screen for epigenetic alterations in the BMP-2 
gene, Caki-1 and Caki-2 cells were treated in duplicate 
with 5-aza-2′-deoxycytidine (5-aza-dC, 5 μmol/L), then 
cultured cells were harvested after 4 days of treatment. 
Using cDNA, the difference in expression level of the 
BMP-2 mRNA transcripts before and after 5-aza-dC 
treatment was analyzed with the 7500 Fast Real-Time 
PCR System (Applied BioSystem).
Methylation analysis and bisulfite DNA 
sequencing
Genomic DNA (100 ng) was modified with 
sodium bisulfite using a commercial kit (Invitrogen Life 
Technologies, San Diego, CA). Based on the functional 
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promoter sequence of the BMP-2 gene [13], methylation- 
and non-methylation-specific primers were designed using 
MethPrimer. The regions amplified by these primers have 
19 CpG sites and their relationship to the CpG sites are 
shown in Figure 2A. For methylation-specific PCR (MSP), 
a second round of nested PCR (MSP and USP) was done 
using the universal PCR product amplified by Uni-S and 
Uni-AS primers as a template. The first universal primer 
sets had no CpG sites in either the forward or reverse 
primer. For each assay, the absence of a DNA template 
served as a negative control. The primer sequences for 
universal, MSP, and USP are shown in Figure 2B. The 
MSP and USP products were analyzed following 2% 
agarose gel electrophoresis. For bisulfite DNA sequencing, 
1 µl of bisulfite-modified DNA was amplified using a pair 
of universal primers (Uni-S and Uni-AS) in a total volume 
of 20 μL. Sequencing of the PCR products using either a 
forward or reverse universal primer was done according 
to the manufacturer’s instructions (Applied Biosystems, 
Foster City, CA). 
transfection
For BMP-2 overexpression, Caki-1 and Caki-2 
cells were transfected with a pCMV6-ENTRY vector 
expressing human BMP-2 cDNA or an empty pCMV6-
ENTRY vector (OriGene Technologies, Rockville, 
MD) using X-treme gene HD Transfection Reagent 
(Roche Diagnostics, Indianapolis, IN), according to the 
manufacturer’s protocol.
Mts assay
Cells were plated in triplicate in 96-well 
microplates at a density of 3×103 cells per well, 
then transfected with BMP-2 the next day. At the 
desired time points, the number of viable cells was 
determined by adding a 3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2- (4-sulfophenyl) 
-2H-tetrazolium-based CellTiter 96 Aqueous One Solution 
Reagent (Promega, Madison, WI) to each well and 
measuring absorbance at 490 nm with a SPECTRA MAX 
190 plate reader (Molecular Devices, Sunnyvale, CA).
Migration and invasion assay
Cell migration was evaluated using a wound-
healing assay. Cells were plated in 6-well dishes and 
cell monolayers were scraped using a P-20 micropipette 
tip. Wound closure was monitored and percent closure 
measured. Cell invasion assay was performed using 
modified Boyden Chambers consisting of transwell-pre-
coated Matrigel membrane filter inserts with 8 micro-pores 
in 24-well tissue culture plates (BD Biosciences, Bedford, 
MA, USA). Transfected cells were re-suspended in culture 
medium without FBS and placed in the upper chambers 
in triplicate. After 48 hours of incubation at 37°C, cells 
migrating through the membrane were stained. The results 
are expressed as invaded cells quantified at OD 560 nm.
colony formation assay
Colony formation assays were performed using a 
CytoSelectTM 96-Well Cell Transformation Assay (Cell 
Bioloabs). Briefly, 600 transfected cells were seeded into 
each well of 96-well microplates and incubated for 8 days. 
Then, quantitation of colony formation was determined 
by adding MTT solution to each well and measuring 
absorbance at 570 nm with a SPECTRA MAX 190 plate 
reader (Molecular Devices, Sunnyvale, CA).
Apoptosis assay
Fluorescence-activated cell-sorting (FACS) 
analysis for apoptosis was done at 24 and 48 hours post-
transfection, using an annexin V-fluorescein isothiocyanate 
(FITC)/7-amino-actinomycin D (7-AAD) staining 
system (BD Biosciences, San Diego, CA) and a Cell Lab 
QuantaTM SC MPL (Beckman Coulter, Fullerton, CA). 
Cells stained with annexin V-FITC only (early apoptotic), 
or both annexin V-FITC and 7-AAD (late apoptotic) were 
considered to be apoptotic cell fractions.
Western blot analysis
Whole cell extracts were prepared using 
radioimmunoprecipitation assay buffer (RIPA; Thermo 
Scientific, Rockford, IL) containing a protease inhibitor 
cocktail (Roche Diagnostics, Basel, Switzerland). Protein 
quantification was done using a BCA protein assay kit 
(Pierce) according to the manufacturer’s instructions. 
Total cell protein (15-20 μg) was used for western blotting. 
Samples were transferred to PVDF membranes, then 
immersed in 3% skim milk with antibodies against BMP-2 
(#ab14933, Abcam, Cambridge, MA), Smad1/5/8 (#12656 
Cell Signaling Technology), phospho-SMAD1/5/8 
(#sc-12353-R, Santa Cruz), p21WAF1/CIP1 (#2947, Cell 
Signaling Technology), p27KIP1 (#2552, Cell Signaling 
Technology), Cdk2 (#2546, Cell Signaling Technology), 
Caspase-3 (#9662, Cell Signaling Technology), Cleaved 
Caspase-3 (#9661, Cell Signaling Technology), and 
GaDD45α (#4632, Cell Signaling Technology) overnight 
at 4°C. Blots were washed in TBS containing 0.1% 
Tween20 and labeled with horseradish peroxidase 
conjugated secondary anti-rabbit antibody (Cell Signaling 
Technology). Specific complexes were visualized with an 
ECHO chemiluminescence (ECL) detection system (GE 
Healthcare, Little Chalfont, UK) using the Chemidoc 
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imaging system (Bio Rad, CA, USA). The protein 
expression levels are expressed relative to GAPDH.
Immunohistochemical analysis
Of the 96 patients with RCC who underwent 
radical nephrectomy, specimens from 84 were available 
for evaluation by immunostaining. Normal control 
tissues were obtained from 62 of those 84 RCC patients. 
Immunostaining of BMP-2 was performed using an 
UltraVision Detection System (Thrmo Scientific) 
according to the manufacturer’s instructions. After 12 
hours of incubation with a rabbit polyclonal antibody 
for BMP-2 (1: 250, #ab14933, Abcam), DAB was 
added as a chromogen, followed by counterstaining with 
hematoxylin. For BMP-2 expression, cytoplasmic and 
nuclear expression was analyzed according to the intensity 
of positive cells using Image J software (http://rsb.info.
nih.gov/ij) and ranked on an overall scale from 0 to 3; with 
0 indicating the absence of staining; 1, weak staining; 2, 
moderate staining; and 3, strong staining. 
statistical analysis
Values are presented as the mean ± standard error 
based on results obtained from at least 3 independent 
experiments. All data were analyzed using the StatView 
V statistical package (SAS Institute, Inc., Cary, NC). 
Relationships between 2 variables and numerical values 
were analyzed using a nonparametric Mann-Whitney 
U test or a two-tailed unpaired Student’s t-test. A chi-
square test was used for analyzing the correlation between 
clinicopathologic parameters and BMP-2 methylation 
status. Correlations between 2 continuous variables were 
analyzed using Spearman’s rank correlation. Survival 
curves were constructed using the Kaplan-Meir method 
and differences between 2 curves were analyzed with a log 
rank test. Univariate and multivariate analyses for overall 
(OS) survival were performed using a Cox proportional 
hazards regression model. A P value of less than 0.05 was 
considered to be statistically significant. 
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